

Contents

Acknowledgments, ix
Praise for the First Edition, xi
About the Author, xiii
How to Use This Book, xv

CHAPTER 1	An Introduction to Cancer Cell Biology and Genetics, 1
	1.1 Introduction, 2
	1.2 DNA Damage Is the Cause of Every Cancer, 3
	1.3 The Defining Features (Hallmarks) of Cancer Cells, 18
	1.4 Variation Among Cancer Cells in a Single Tumor, 20
	1.5 Cancer's Relationship with Our Immune System, 22
	1.6 The Cancer Microenvironment, 30
	1.7 Cancer Spread/Metastasis, 36
	1.8 Cancer Stem Cells, 39
	1.9 Unique Properties of Hematological Cancers, 40
	1.10 Obstacles that Prevent Us from Curing Cancer, 46
	1.11 Final Thoughts, 52

CHAPTER 2	Monoclonal Antibodies and Small Molecules as Cancer Treatments, 61
	2.1 Introduction, 62
	2.2 Antibody-Based Cancer Treatments, 66
	2.3 Small Molecule Cancer Treatments, 83
	2.4 Treatment Combinations, 99
	2.5 Final Thoughts, 100

CHAPTER 3	Treatments that Target Cell Communication, 109
	3.1 Introduction, 110
	3.2 Growth Factor-Controlled Signaling Pathways, 112
	3.3 Growth Factor Receptors in Cancer, 118
	3.4 Drugs that Target EGFR, 121
	3.5 Drugs that Target HER2, 131
	3.6 Drugs that Block Other Growth Factor Receptors, 138
	3.7 Targeting the MAPK Signaling Pathway, 145

- 3.8 Targeting the PI3K/AKT/mTOR Signaling Pathway, 156
- 3.9 Targeting the JAK-STAT Pathway, 164
- 3.10 Bcr-Abl Inhibitors, 167
- 3.11 Final Thoughts, 169

CHAPTER 4

More Targets and Treatments, 183

- 4.1 Angiogenesis Inhibitors, 184
- 4.2 Antibody Conjugates, 195
- 4.3 PARP Inhibitors, 202
- 4.4 CDK Inhibitors and Other Cell Cycle-Targeted Treatments, 211
- 4.5 Hedgehog Pathway Inhibitors, 219
- 4.6 Targeting Epigenetic Enzymes, 222
- 4.7 Targeting Cell Survival, 226
- 4.8 Targeting B Cell Receptor Signaling, 230
- 4.9 Nuclear Transport Inhibitors, 235
- 4.10 Proteasome Inhibitors, 236
- 4.11 Final Thoughts, 240

CHAPTER 5

Immunotherapy with Checkpoint Inhibitors, 253

- 5.1 The Importance of T Cells, 254
- 5.2 An Introduction to Immune Checkpoint Inhibitors, 256
- 5.3 How Checkpoint Inhibitors Work, 260
- 5.4 Lessons Learned from Checkpoint Inhibitor Trials, 261
- 5.5 Why Some Patients Benefit from Checkpoint Inhibitors and Others Don't, 271
- 5.6 Biomarkers of Response to Checkpoint Inhibitors, 275
- 5.7 Checkpoint Inhibitor Combinations, 282
- 5.8 Novel Checkpoint Inhibitors and Activators, 287
- 5.9 Final Thoughts, 290

CHAPTER 6

Other Forms of Immunotherapy, 301

- 6.1 Introduction, 302
- 6.2 Naked Antibodies that Trigger an Immune Response, 303
- 6.3 Immunomodulators and CELMoDs, 304
- 6.4 Introduction to Adoptive Cell Therapies, 307
- 6.5 Tumor-Infiltrating Lymphocyte Therapy, 308
- 6.6 CAR T Cell Therapy, 312
- 6.7 TCR-Engineered T Cell Therapy, 326
- 6.8 Cell Therapy with Other White Blood Cells, 331
- 6.9 T Cell Engagers, 332
- 6.10 Cancer Treatment Vaccines, 340
- 6.11 Final Thoughts, 351

CHAPTER 7

Treatments Relevant to Individual Cancer Types, 359

- 7.1 Introduction, 359
- 7.2 Treatments for Breast Cancer, 361
- 7.3 Treatments for Bowel and Anal Cancers, 364
- 7.4 Treatments for Lung Cancer, 367
- 7.5 Treatments for Prostate, Testicular, and Penile Cancers, 371
- 7.6 Treatments for Head and Neck Cancer, 374
- 7.7 Treatments for Esophageal, Gastroesophageal Junction, and Stomach Cancers, 376
- 7.8 Treatments for Pancreatic, Bile Duct, and Primary Liver Cancers, 378
- 7.9 Treatments for Kidney and Bladder Cancers, 381
- 7.10 Treatments for Ovarian Cancer, 383
- 7.11 Treatments for Other Gynaecological Cancers, 384
- 7.12 Treatments for Brain and CNS Cancers, 386
- 7.13 Treatments for Skin Cancer, 388
- 7.14 Treatments for B Cell and T Cell Leukemias, 391
- 7.15 Treatments for Non-Hodgkin Lymphomas, 393
- 7.16 Treatments for Hodgkin Lymphoma and Myeloma, 395
- 7.17 Treatments for Myeloid Cell Cancers, 397
- 7.18 Treatments for Childhood Cancers, 400

Appendix, 411

Glossary of Terms, 413

Index, 431

